Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2011-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.2011.573624PMID 21457083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunological Foundations to the Quest for New Vaccine Adjuvants

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

  2009influential reference
• Follicular helper T cells: lineage and location.

  2009cited by this paper
• Mechanism of action of licensed vaccine adjuvants.

  2009cited by this paper
• New horizons in adjuvants for vaccine development.

  2009cited by this paper
• Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.

  2009cited by this paper
• Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

  2009influential reference
• Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.

  2009cited by this paper
• The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding

  2009cited by this paper
• The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

  2009cited by this paper
• Inflammatory signals in dendritic cell activation and the induction of adaptive immunity

  2009influential reference
• Mechanism of action of clinically approved adjuvants.

  2009influential reference
• Towards an understanding of the adjuvant action of aluminium

  2009cited by this paper
• Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

  2009cited by this paper
• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

  2009cited by this paper
• AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1

  2009cited by this paper
• Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant

  2008influential reference
• Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

  2008influential reference
• Vaccine adjuvants alter TCR-based selection thresholds.

  2008cited by this paper
• A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.

  2008cited by this paper
• Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.

  2008cited by this paper
• Antigen presentation by monocytes and monocyte-derived cells.

  2008cited by this paper
• Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.

  2008cited by this paper
• Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

  2008cited by this paper
• Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature.

  2008cited by this paper
• Cutting Edge: T Cells Respond to Lipopolysaccharide Innately via TLR4 Signaling1

  2007cited by this paper
• New hepatitis B vaccine formulated with an improved adjuvant system

  2007influential reference
• Signaling to NF-kappaB by Toll-like receptors.

  2007cited by this paper
• Aluminum Hydroxide Adjuvants Activate Caspase-1 and Induce IL-1β and IL-18 Release1

  2007influential reference
• Signaling to NF-?B by Toll-like receptors

  2007cited by this paper
• GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

  2007cited by this paper
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

  2007cited by this paper
• Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.

  2007cited by this paper
• The perfect mix: recent progress in adjuvant research

  2007cited by this paper
• Triggering TLR signaling in vaccination.

  2006cited by this paper
• Toll-like receptors and IFN-alpha: partners in autoimmunity.

  2006cited by this paper
• Toll-like receptors in systemic autoimmune disease

  2006cited by this paper
• Intracellular pattern recognition receptors in the host response

  2006cited by this paper
• Toll-like receptors and IFN-α: partners in autoimmunity

  2006cited by this paper
• Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt

  2006cited by this paper
• Chapter 2: The burden of HPV-related cancers.

  2006cited by this paper
• Pathogen recognition and innate immunity.

  2006cited by this paper
• Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

  2006cited by this paper
• Translating innate immunity into immunological memory: implications for vaccine development.

  2006cited by this paper
• Toll‐like receptor stimulation as a third signal required for activation of human naive B cells

  2006cited by this paper
• Comparison of cervical and blood T‐cell responses to human papillomavirus‐16 in women with human papillomavirus‐associated cervical intraepithelial neoplasia

  2006cited by this paper
• (How) do aluminium adjuvants work?

  2006influential reference
• How bacteria and their products provide clues to vaccine and adjuvant development.

  2006influential reference
• Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

  2006cited by this paper
• Control of B-cell responses by Toll-like receptors

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• The papillomavirus life cycle.

  2005cited by this paper
• The carcinogenicity of human papillomavirus types reflects viral evolution.

  2005cited by this paper
• Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro.

  2005influential reference
• Aluminium adjuvants--in retrospect and prospect.

  2004influential reference
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

  2004cited by this paper
• Toll-like receptor control of the adaptive immune responses

  2004influential reference
• Against which human papillomavirus types shall we vaccinate and screen? the international perspective

  2004cited by this paper
• Classification of papillomaviruses.

  2004cited by this paper
• Natural History of Human Papillomavirus Type 16 Virus-Like Particle Antibodies in Young Women

  2004cited by this paper
• Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

  2004influential reference
• Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells

  2003influential reference
• The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells.

  2003cited by this paper
• Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A

  2003cited by this paper
• Molecular identification of a danger signal that alerts the immune system to dying cells

  2003cited by this paper
• Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells

  2002cited by this paper
• The Danger Model: A Renewed Sense of Self

  2002influential reference
• Monophosphoryl Lipid A Activates Both Human Dendritic Cells and T Cells1

  2002cited by this paper
• Mechanisms of stimulation of the immune response by aluminum adjuvants.

  2002influential reference
• The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.

  2002cited by this paper
• Human papillomavirus immortalization and transformation functions.

  2002cited by this paper
• A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types.

  2001cited by this paper
• Toll-Like Receptor 4, But Not Toll-Like Receptor 2, Is a Signaling Receptor for Escherichia and Salmonella Lipopolysaccharides1

  2000cited by this paper
• Cutting Edge: Repurification of Lipopolysaccharide Eliminates Signaling Through Both Human and Murine Toll-Like Receptor 21

  2000cited by this paper
• A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

  1997influential reference
• Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus

  1996cited by this paper
• Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.

  1996cited by this paper
• Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

  1995cited by this paper
• Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection

  1995cited by this paper
• Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

  1994influential reference
• Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

  1992influential reference
• Approaching the asymptote? Evolution and revolution in immunology.

  1989cited by this paper
• Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium.

  1982influential reference
• Rate of Disappearance of Diphtheria Toxoid injected into Rabbits and Guinea-Pigs: Toxoid precipitated with Alum.

  1931cited by this paper

• Aluminum adjuvants differentially induce IL-1β release in vitro yet share NLRP3 inflammasome-independent adjuvant effects in vivo

  2026cites this paper
• Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections

  2023cites this paper
• Two Modes of Th1 Polarization Induced by Dendritic-Cell-Priming Adjuvant in Vaccination

  2023cites this paper
• Application of Traditional Vaccine Development Strategies to SARS-CoV-2

  2023cites this paper
• Methods of prevention of vaginal intraepithelial neoplasia in HPV-positive patients under radical surgery

  2023cites this paper
• Application of Traditional Vaccine Development Strategies to SARS-CoV-2

  2022cites this paper
• Animal Shelter, Vaccination and Welfare

  2021cites this paper
• Emergence of Oncogenic High-Risk Human Papillomavirus Types and Cervical Cancer

  2020cites this paper
• Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study

  2020cites this paper
• Recombinant Technologies to Improve Ruminant Production Systems: The Past, Present and Future

  2020cites this paper
• Vaginal Intraepithelial Neoplasia: Diagnostics, Treatment, and Prevention

  2020cites this paper
• Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen

  2019cites this paper
• Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus

  2019cites this paper
• Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.

  2019cites this paper
• Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

  2019cites this paper
• Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.

  2019cites this paper
• The nonavalent vaccine: a review of high-risk HPVs and a plea to the CDC.

  2019cites this paper
• Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection

  2018cites this paper
• Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development

  2018cites this paper
• The vaccine adjuvant alum promotes IL‐10 production that suppresses Th1 responses

  2018cites this paper
• Systems analysis of human vaccine adjuvants.

  2018cites this paper
• DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination

  2018cites this paper
• Toward a virosomal respiratory syncytial virus vaccine with a built-in lipophilic adjuvant : A vaccine candidate for the elderly and pregnant women

  2018cites this paper
• The Sulfated Polysaccharides of Brown Algae and Products of Their Enzymatic Transformation as Potential Vaccine Adjuvants

  2018cites this paper
• Exploration of the Mechanisms of Adjuvanticity for Toll-like Receptor Agonists

  2017cites this paper
• Respiratory syncytial virus: an overview of infection biology and vaccination strategies

  2017cites this paper
• The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches

  2017cites this paper
• Evaluation of long-term immunological responses following reduced-dose quadrivalent human papillomavirus vaccine schedules in Fiji

  2017cites this paper
• A New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2+ T Cells

  2017cites this paper
• Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines

  2016cites this paper
• Monophosphoryl lipid A-induced pro-inflammatory cytokine expression does not require CD14 in primary human dendritic cells

  2016cites this paper
• Vaccination against Viruses

  2016cites this paper
• Strategies for designing synthetic immune agonists

  2016cites this paper
• Molecular signatures of vaccine adjuvants.

  2015cites this paper
• Raising expectations for subunit vaccine.

  2015cites this paper
• Next generation prophylactic human papillomavirus vaccines.

  2015cites this paper
• HPV and cancer 2 Next generation prophylactic human papillomavirus vaccines

  2015cites this paper
• Particulate inorganic adjuvants: recent developments and future outlook

  2015cites this paper
• Recent Advances of Vaccine Adjuvants for Infectious Diseases

  2015cites this paper
• Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract

  2015cites this paper
• Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.

  2015cites this paper
• Women and Children’s Health

  2014cites this paper
• Recent progress in dengue vaccine development

  2014cites this paper
• Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

  2014cites this paper
• Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.

  2014cites this paper
• Latest developments and future directions in dengue vaccines

  2014cites this paper
• Vaccines, reverse vaccinology, and bacterial pathogenesis.

  2013cites this paper
• Role and Application of Adjuvants and Delivery Systems in Vaccines

  2013cites this paper
• Thimerosal and Other Vaccine Additives

  2013cites this paper
• The mRNA-HPV test utilization in the follow up of HPV related cervical lesions.

  2013cites this paper
• Reverse Vaccinology , and Bacterial Pathogenesis

  2013cites this paper
• Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.

  2013cites this paper
• A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats

  2013cites this paper
• Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice

  2012cites this paper
• A review of clinical trials of human papillomavirus prophylactic vaccines.

  2012cites this paper
• License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems.

  2012cites this paper
• Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV.

  2012cites this paper
• New adjuvants in evolving vaccine strategies

  2011cites this paper
• Toll Like Receptors Play a Role in General Immunity, Eye Infection and Inflammation: TLRs for Nanodelivery

  2011cites this paper